Group 1 - The A-share chemical pharmaceutical sector is experiencing a volatile correction, with companies such as Haichen Pharmaceutical and Yong'an Pharmaceutical both declining over 9% [1] - Other companies including Yipinhong, Hasanlian, Tonghua Jinma, Hanyu Pharmaceutical, and Hehua Co. have also seen declines of around 5% [1]

Core Insights - The Shanghai Composite Index rose by 0.43% on June 3, with 20 out of 28 sectors experiencing gains, particularly in the beauty care and textile sectors, which increased by 3.86% and 2.53% respectively [1] - The pharmaceutical and biotechnology sector saw a rise of 1.78%, with a net inflow of 9.17 billion yuan in capital [1] - Among the 475 stocks in the pharmaceutical sector, 416 stocks increased, with 14 hitting the daily limit up, while 54 stocks declined [1] Capital Flow Analysis - The pharmaceutical sector had 221 stocks with net capital inflows, with 6 stocks receiving over 100 million yuan in net inflows. Leading the inflow was Huahai Pharmaceutical with 266.1 million yuan, followed by Qianhong Pharmaceutical and Hehua Co., which received 201.5 million yuan and 168 million yuan respectively [1] - The outflow list included 6 stocks with net outflows exceeding 50 million yuan, with the highest outflows from Ruizhi Pharmaceutical, Hengrui Medicine, and Mindray Medical, which saw outflows of 237 million yuan, 110 million yuan, and 109 million yuan respectively [2] Pharmaceutical Sector Performance - The top gainers in the pharmaceutical sector included: - Huahai Pharmaceutical: +7.63%, turnover rate 7.71%, capital flow 266.1 million yuan - Qianhong Pharmaceutical: +10.05%, turnover rate 17.02%, capital flow 201.5 million yuan - Hehua Co.: +9.95%, turnover rate 18.47%, capital flow 167.7 million yuan [1] - The top decliners included: - Ruizhi Pharmaceutical: -13.15%, turnover rate 34.15%, capital flow -236.7 million yuan - Hengrui Medicine: -0.26%, turnover rate 0.68%, capital flow -109.7 million yuan - Mindray Medical: -3.02%, turnover rate 0.58%, capital flow -108.9 million yuan [2] ETF Insights - The Hang Seng Medical ETF, which tracks the Hang Seng Hong Kong-listed biotechnology index, experienced a 5-day increase of 3.59% with a net inflow of 9.86 million yuan [5]

Group 1 - The CRO concept index rose by 3.41%, ranking 6th among concept sectors, with 59 stocks increasing in value [1] - Leading stocks in the CRO sector included Lianhua Technology and Hehua Co., which hit the daily limit, while Tianyu Co. and Haitai Bio saw significant gains of 19.72% and 13.18% respectively [1] - The stocks with the largest declines included *ST Shuangcheng, Fosun Pharma, and Kailai Ying, which fell by 3.08%, 0.39%, and 0.24% respectively [1] Group 2 - The CRO sector experienced a net inflow of 0.45 billion yuan, with 25 stocks receiving net inflows, and 14 stocks attracting over 10 million yuan [2] - Hehua Co. led the net inflow with 1.68 billion yuan, followed by Lianhua Technology and Haoyuan Pharmaceutical with net inflows of 834.83 million yuan and 749.80 million yuan respectively [2] - The top stocks by net inflow ratio included Hehua Co. at 28.79%, Haoyuan Pharmaceutical at 12.05%, and Nearshore Protein at 11.73% [3] Group 3 - The trading volume and turnover rates for leading stocks in the CRO sector were notable, with Hehua Co. achieving a turnover rate of 18.47% and Lianhua Technology at 13.17% [3] - Other significant stocks included Yaosheng Technology and Sichuan Shuangma, which also showed positive performance with gains of 5.21% and 5.29% respectively [3] - Stocks like Tianyu Co. and Ruizhizhi Pharmaceutical had substantial trading activity, with Tianyu Co. rising by 19.72% and Ruizhizhi Pharmaceutical by 13.15% [5]

Core Viewpoint - The CRO (Contract Research Organization) sector has shown a positive performance with a 1.51% increase, ranking second among concept sectors, driven by significant gains in specific stocks like New Tian Di, which hit a 20% limit up [1][2]. Sector Performance - The CRO concept sector saw 42 stocks rise, with New Tian Di leading at a 20% increase, followed by Yang Guang Nuo He at 12.55%, Rui Zhi Yi Yao at 8.05%, and Hong Bo Yi Yao at 7.73% [1][2]. - Conversely, stocks like *ST Shuang Cheng, Si Chuan Shuang Ma, and Jin An Dan Bai experienced declines of 5.01%, 3.73%, and 3.19% respectively [1][2]. Capital Flow - The CRO sector experienced a net outflow of 507,500 yuan, with 29 stocks receiving net inflows. New Tian Di topped the list with a net inflow of 86,619,800 yuan, followed by Kang Long Hua Cheng with 58,064,600 yuan and Tai Ge Yi Yao with 49,707,000 yuan [2][3]. - The net inflow ratios for leading stocks included New Tian Di at 10.25%, Nuo Si Ge at 9.53%, and Kang Long Hua Cheng at 6.78% [3]. Stock Highlights - Key stocks in the CRO sector included: - New Tian Di: 20.02% increase, 57.74% turnover rate, net inflow of 86,619,800 yuan, net inflow ratio of 10.25% [3][4]. - Kang Long Hua Cheng: 2.38% increase, 2.58% turnover rate, net inflow of 58,064,600 yuan, net inflow ratio of 6.78% [3][4]. - Tai Ge Yi Yao: 5.64% increase, 4.82% turnover rate, net inflow of 49,707,000 yuan, net inflow ratio of 3.80% [3][4]. Declining Stocks - Notable declines included: - *ST Shuang Cheng: 5.01% decrease, with a significant net outflow of 1,391,440 yuan [5][6]. - Si Chuan Shuang Ma: 3.73% decrease, with a net outflow of 500,800 yuan [5][6]. - Jin An Dan Bai: 3.19% decrease, with a net outflow of 233,620 yuan [5][6].

证券代码：000953 证券简称：河化股份 公告编号：2025-018 广西河池化工股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1.本次股东大会召开期间无增加、修改提案的情况，不存在否决提案的情况； 2.本次股东大会不存在变更以往股东大会已通过的决议的情况； 3.本次股东大会以现场投票及网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议召开时间：2025 年 5 月 22 日 （星期四）14:30 1.股东出席的总体情况： 通过现场和网络投票的股东 285 人，代表股份 127,148,890 股，占公司有表 决权股份总数的 34.8120％。其中，通过现场投票的股东 2 人，代表股份 124,493,589 股，占公司有表决权股份总数的 34.0850％；通过网络投票的股东 283 人，代表股份 2,655,301 股，占公司有表决权股份总数的 0.7270％。 （2）网络投票时间： A、通过深圳证券交易所交易系统进行网络投票，时间为 202 ...

法律意见书 国浩律师（南宁）事务所受广西河池化工股份有限公司（以下简称"公 司"）的委托，指派李长嘉、黄赟律师（以下简称"本律师"）对公司2024 年年度股东大会（以下简称"本次股东大会"或"本次会议"）召开的全 过程进行见证并出具法律意见。 为出具法律意见，本律师审查了公司提供的有关会议文件、资料，公 司保证已向本律师提供了出具法律意见所必须的、真实的书面材料。 基于对上述文件、资料的审查和见证情况，本律师根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》《广 西河池化工股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本次 股东大会发表法律意见。 法律意见书 法律意见书 国浩律师（南宁）事务所 2012 年第五次临时股东大会的 关于广西河池化工股份有限公司 法律意见书 2024 年年度股东大会的法律意见书 国浩律师（南宁）意字（2024）第 5069-3 号 2012 年第五次临时股东大会的 致：广西河池化工股份有限公司 本律师同意公司将本法律意见书与本次股东大会会议决议一同公告， 并依法对法律意见书承担法律责任 ...

这几只票暗盘资金正在偷偷流入，立即查看>> CRO概念板块短线拉升，河化股份（000953）涨停，金凯生科（301509）、睿智医药（300149）、诺 思格（301333）、昊帆生物（301393）、义翘神州（301047）等纷纷走高。 ...

Financial Performance - In Q1 2025, the net profit attributable to shareholders reached 1.362 million yuan, a significant increase of 217.42% compared to the same period last year, marking a turnaround from losses to profits [3] - The company has implemented cost reduction and efficiency enhancement measures, leading to improved overall profitability [3] Debt Management - The company repaid 60 million yuan of loans from controlling shareholders in Q1 2025 to reduce financial expenses [4] Risk Management - The company does not currently face delisting risk as per the Shenzhen Stock Exchange listing rules, despite concerns over small revenue [4] Business Development - The company plans to actively explore new business opportunities and expand market reach while ensuring compliance and risk control [4][6] - Focus will remain on core business areas, enhancing resource allocation, and increasing competitiveness through market-driven strategies [6] Shareholder Concerns - The restructuring of the controlling shareholder, Ningbo Yinyi Holdings, is ongoing, with a court-approved plan in October 2024 for a combined restructuring of 17 companies [6]

证券代码：000953 证券简称：河化股份 公告编号：2025-017 广西河池化工股份有限公司 关于举办 2024 年度暨 2025 年第一季度 网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广西河池化工股份有限公司（以下简称"公司"）分别于 2025 年 4 月 26 日、 29 日在巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年度报告》《2025 年 第一季度报告》。 为便于广大投资者进一步了解公司业绩和生产经营情况，公司定于 2025 年 5 月 20 日举办 2024 年度暨 2025 年第一季度网上业绩说明会。 一、本次业绩说明会相关安排 1.召开时间：2025 年 5 月 20 日（星期二）15:00-16:30 2.召开方式：本次业绩说明会将采用网络远程的方式举行，投资者可以登录 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈" 栏目参与本次业绩说明会。 3.出席人员：公司董事长施伟光先生；公司董事、总经理江鲁奔先生；公司 独立董事郭益浩先生；公司 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大 遗漏。 一、审议程序 公司于2025年4月24日召开了第十届董事会第二十一次会议，审议通过了《关于公司2024年度利润分配 的议案》，并同意将本议案提交公司股东会审议。 二、公司利润分配议案的基本情况 根据中兴财光华会计师事务所（特殊普通合伙）对本公司出具的2024年度审计报告，2024年度母公司实 现净利润为71,636,798.62元，2024年末未分配利润为-742,375,438.22元。根据《公司法》》《公司章 程》的有关规定，公司累计亏损未经全额弥补之前，不得向股东派发股利或以资本公积转增股本，故公 司2024年度拟不进行利润分配及公积金转增股本。 四、备查文件 三、现金分红方案的具体情况 （一）现金分红方案指标 ■ （二）现金分红方案合理性说明 1.《审计报告》（中兴财光华审会字（2025）第226015号） 2.公司《第十届董事会第二十一次会议决议》 3.公司《第十届监事会第十三次会议决议》 根据上述指标，对照《深圳证券交易所股票上市规则》，公司2024 ...